Evidence map›Paper›PMID 36656020›Full record

ArticleMicrobiology spectrum2023

Stability of the COVID-19 At-Home Test after Exposure to Extreme Temperatures.

Erin Gick, Stephen McCune, Jamie P Deeter

Abstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Erin GickRoche Diagnostics Corporation, Indianapolis, Indiana, USA.
Stephen McCuneRoche Diagnostics Corporation, Indianapolis, Indiana, USA.
Jamie P DeeterRoche Diagnostics Corporation, Indianapolis, Indiana, USA.ORCID 0000-0001-9851-3215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To ensure sufficient sensitivity and specificity of lateral flow tests for the detection of SARS-CoV-2 antigen, manufacturers recommend appropriate conditions for storage, including a temperature range. However, there is a high likelihood that kits will be exposed to temperatures outside of this range during transit to some regions. In this prospective study, we evaluated the sensitivity and specificity of the COVID-19 At-Home Test kits (manufactured by SD Biosensor/distributed by Roche) currently being delivered through a US Government program, after exposure to a range of hot and cold temperatures. COVID-19 At-Home Test kits were stored at up to 5 different temperatures: frozen (-4.0°F [-20.0°C]), refrigerated (42.8°F [6.0°C]), room temperature (68.0°F [20.0°C]), warm (98.0°F [36.7°C]), and excessive heat (118.0 to 126.0°F [47.8 to 52.2°C]) for 24 h and left at room temperature for 60, 90, or 120 min before use. Test kits were also stored for 48 h, 1 week, or 2 weeks in frozen, warm, and excessive heat conditions, and left for 60 or 120 min before use. In each scenario (storage temperature + time at room temperature), 5 positive and 5 negative control samples were applied, and line intensity was recorded using a color scale (0 to 100%). In every scenario, every positive sample resulted in strong signal intensity (≥26%), and every negative sample returned a negative result. This study suggests that exposure of up to 2 weeks to extreme temperatures, such as those that may occur in transit, does not impact the stability of the COVID-19 At-Home Test.

Indexed as

COVID-19Hot TemperatureHumansProspective StudiesSARS-CoV-2Temperatureextreme heatfreezingpoint-of-care testingSARS-CoV-2

Identifiers

PMID36656020
PMCPMC9927546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.